Health policy, communications and advocacy, grounded in evidence.
Policy analysis, public affairs, health communications and advocacy campaigns for life sciences companies, NGOs, governments and patient groups.
Good evidence does not change policy on its own.
Decision makers weigh evidence alongside budgets, politics and public opinion. Without a clear message and the right audience, strong evidence is easily overlooked.
Evidence first, then the message.
We pair health economics and policy analysis with communications and advocacy, so every message is grounded in data and aimed at the people who decide.
- Which stakeholders shape this decision?
- How do policies compare across countries?
- How do we explain the evidence to non-specialists?
- How do we build a coalition for change?
Health policy and public affairs
Clear evidence for the decisions behind the decisions.
- Situation analysis and multi-country policy benchmarking
- Stakeholder mapping and engagement planning
- Rare disease and access policy analysis
- Policy briefs, white papers and consultation responses
- Policy advocacy and public affairs for companies, NGOs and patient groups
- Policy horizon scanning and international policy analysis
- Global access policy and multi-market uptake insight
- Issues management
- Government affairs and engagement with senior decision makers
Healthcare communications
Science and value, written so people act on them.
- Medical writing and publications
- Plain-language evidence summaries
- PR, corporate and crisis communications
- Executive and sponsored content, newsletters and market intelligence briefings
- Digital and social media
- Congress abstracts, posters and stakeholder engagement
Advocacy, campaigns and public affairs
Evidence alone changes nothing if the right people never hear it.
- Health communications and public awareness campaigns
- Policy advocacy and public affairs
- Media relations
- Coalition building and community mobilisation
- Digital and social media
- Corporate communications and crisis communications
Stakeholder mapping, interactive.
Drag each stakeholder across the grid. Their position on influence and interest sets the engagement approach, which is how every policy and communications plan begins.
Illustrative data and models, for demonstration only.
From the evidence to the decision makers.
- 01
Situation analysis
Policy landscape, benchmarking and the evidence base.
- 02
Stakeholder mapping
Who decides, who influences and what each needs to hear.
- 03
Message and materials
Policy briefs, plain-language summaries and campaign content.
- 04
Engagement
Public affairs, media relations, coalitions and campaigns.
Our analysis on this.
US MFN drug pricing: what it means for UK and European launches
US MFN drug pricing explained: GLOBE, GUARD and GENEROUS, reference baskets, the GDP (PPP) adjuster and what it means for UK, Irish and EU launch prices.
Read the analysisJCA PICO scoping: how it works and what the first reports show
How PICO scoping works in the EU joint clinical assessment, what the first published JCA reports show, and how to plan SLRs and indirect comparisons for it.
Read the analysisOne evidence plan for NICE and the EU JCA
How NICE and EU JCA evidence requirements align and diverge, and how to design one SLR and indirect treatment comparison programme to serve both.
Read the analysisGLP-1s in 2026: the price fell, the access gap did not
HTA and payer decisions for GLP-1 obesity medicines across the US, England, France, Germany and Ireland.
Read the analysisOne Regulation. 27 Speeds. The JCA Readiness Index
Which EU member states are ready for joint clinical assessment, and what that means for 2027 launches.
Read the analysis